Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.56 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GYS1 | P13807 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289574 | 1.00 | P2RX7 (0.56) | P2RX7CAPN1KMT2AGAAITGB1 | |
| SCHEMBL288652 | 1.00 | P2RX7 (0.56) | P2RX7CAPN1KMT2AGAAITGB1 | |
| SCHEMBL1612123 | 0.91 | CAPN1 (0.63) | P2RX7CAPN1HCRTR1HCRTR2 | |
| SCHEMBL288455 | 0.91 | CAPN1 (0.63) | P2RX7CAPN1HCRTR1HCRTR2 | |
| SCHEMBL1162700 | 0.91 | P2RX7 (0.54) | P2RX7CAPN1KMT2AGAAITGB1 | |
| SCHEMBL1162612 | 0.91 | P2RX7 (0.54) | P2RX7CAPN1KMT2AGAAITGB1 | |
| SCHEMBL28270409 | 0.91 | P2RX7 (0.54) | P2RX7CAPN1KMT2AGAAITGB1 | |
| SCHEMBL5741011 | 0.90 | KMT2A (0.54) | P2RX7CAPN1KMT2AGAAITGB1 | |
| SCHEMBL19975206 | 0.88 | P2RX7 (0.54) | P2RX7KMT2AGAAALDH1A1HCRTR1 | |
| SCHEMBL19975137 | 0.88 | P2RX7 (0.54) | P2RX7CAPN1KMT2AGAAITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | claimed |
| EP-1384713-A1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | claimed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | claimed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | claimed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | claimed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | claimed |
| CN-1350458-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2002-05-22 | — | — | CN | claimed |
| EP-0187052-B1 | ADAMANTAN AMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | S.A. PANMEDICA Société dite: (FR) | 1990-01-31 | — | — | EP | claimed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2023164680-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3919056-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | Global Blood Therapeutics, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-2970308-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-4670562-A | MEMORY ENHANCEMENT | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1987-06-02 | — | — | US | disclosed |
| US-4652567-A | Benzo(c)-1,5-naphthyridines useful for treating a patient having drug induced memory impairment in need of memory enhancement | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1987-03-24 | — | — | US | disclosed |
| EP-0197318-A1 | Benzo[C]-1,5-naphthyridines, a process and intermediates for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1986-10-15 | — | — | EP | disclosed |
| EP-0015773-B1 | N-(6-((ACYLAMINOACYLAMINO OR AMINOACYLAMINO)PHENYL) 1,2-DIHYDRO-2-OXONICOTINYL)PENICILLIN COMPOUNDS, PROCESSES FOR THEIR PRODUCTION AND COMPOSITIONS CONTAINING THEM | WARNER-LAMBERT COMPANY (US) | 1983-07-20 | — | — | EP | disclosed |
| US-4278681-A | N-/6-//ACYLAMINOACYLAMINO OR AMINOACYLAMINO/PHENYL/-1,2-DIHYDRO-2-OXONICOTINYL/PENICILLINS | WARNER-LAMBERT CO. (US) | 1981-07-14 | — | — | US | disclosed |
| EP-0015773-A2 | N-(6-((acylaminoacylamino or aminoacylamino)phenyl) 1,2-dihydro-2-oxonicotinyl)penicillin compounds, processes for their production and compositions containing them | WARNER-LAMBERT COMPANY (US) | 1980-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | P2RX7 4597/4885CAPN1 2059/4885KMT2A 2167/4885 |
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | P2RX7 1179/4885CAPN1 105/4885KMT2A 2920/4885 |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | P2RX7 4597/4885CAPN1 2059/4885KMT2A 2167/4885 |
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | P2RX7 4597/4885CAPN1 2059/4885KMT2A 2167/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | P2RX7 712/4885CAPN1 86/4885KMT2A 2410/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | P2RX7 1179/4885CAPN1 105/4885KMT2A 2920/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | P2RX7 1179/4885CAPN1 105/4885KMT2A 2920/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | P2RX7 1179/4885CAPN1 105/4885KMT2A 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.